Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib versus niraparib + bevacizumab with platinum-taxane chemotherapy in newly diagnosed advanced ovarian cancer
2021-001271-16Phase 3Active
- Sponsor
- AGO Research
- Start
- Oct 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of niraparib, bevacizumab, carboplatin and paclitaxel in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by AGO Research. Primary endpoint: Progression-free survival. Started Oct 2021; status: active.
02
Drugs
niraparibbevacizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2021-001271-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001271-16.